These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 14870962)

  • 1. Ziprasidone in Huntington's disease: the first case reports.
    Bonelli RM; Mayr BM; Niederwieser G; Reisecker F; Kapfhammer HP
    J Psychopharmacol; 2003 Dec; 17(4):459-60. PubMed ID: 14870962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone: efficacy and safety in patients with bipolar disorder.
    Patel NC; Keck PE
    Expert Rev Neurother; 2006 Aug; 6(8):1129-38. PubMed ID: 16893341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perospirone in treatment of Huntington's disease: a first case report.
    Roppongi T; Togo T; Nakamura S; Asami T; Yoshimi A; Shiozaki K; Kato D; Kawanishi C; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):308-10. PubMed ID: 16887250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.
    Lundin A; Dietrichs E; Haghighi S; Göller ML; Heiberg A; Loutfi G; Widner H; Wiktorin K; Wiklund L; Svenningsson A; Sonesson C; Waters N; Waters S; Tedroff J
    Clin Neuropharmacol; 2010; 33(5):260-4. PubMed ID: 20616707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone treatment of delirium.
    Leso L; Schwartz TL
    Psychosomatics; 2002; 43(1):61-2. PubMed ID: 11927760
    [No Abstract]   [Full Text] [Related]  

  • 6. Huntington's disease: current concepts of therapy.
    Goetz CG; Weiner WJ
    J Am Geriatr Soc; 1979 Jan; 27(1):23-6. PubMed ID: 153351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine.
    Brusa L; Orlacchio A; Moschella V; Iani C; Bernardi G; Mercuri NB
    Mov Disord; 2009 Jan; 24(1):126-9. PubMed ID: 19170197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziprasidone (Geodon) for schizophrenia.
    Med Lett Drugs Ther; 2001 Jun; 43(1106):51-2. PubMed ID: 11402259
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacologic approaches to the treatment of Huntington's disease.
    Venuto CS; McGarry A; Ma Q; Kieburtz K
    Mov Disord; 2012 Jan; 27(1):31-41. PubMed ID: 21997232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute psychosis in a verified Huntington disease gene carrier with subtle motor signs: psychiatric criteria should be considered for the diagnosis.
    Nagel M; Rumpf HJ; Kasten M
    Gen Hosp Psychiatry; 2014; 36(3):361.e3-4. PubMed ID: 24576988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on ziprasidone.
    Green B
    Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with risperidone and memantine in the treatment of Huntington's disease.
    Cankurtaran ES; Ozalp E; Soygur H; Cakir A
    J Natl Med Assoc; 2006 Aug; 98(8):1353-5. PubMed ID: 16916137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington's disease.
    Bouwens JA; Hubers AA; van Duijn E; Cobbaert CM; Roos RA; van der Mast RC; Giltay EJ
    Eur Neuropsychopharmacol; 2014 Aug; 24(8):1248-56. PubMed ID: 24957738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zotepine in Huntington's disease.
    Bonelli RM; Niederwieser G; Lahousen T; Hofmann P
    Hum Psychopharmacol; 2003 Apr; 18(3):227-9. PubMed ID: 12672176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotection in Huntington's disease: a 2-year study on minocycline.
    Bonelli RM; Hödl AK; Hofmann P; Kapfhammer HP
    Int Clin Psychopharmacol; 2004 Nov; 19(6):337-42. PubMed ID: 15486519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amantadine in the akinetic-rigid variant of Huntington's disease.
    Magnet MK; Bonelli RM; Kapfhammer HP
    Ann Pharmacother; 2004; 38(7-8):1194-6. PubMed ID: 15178736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Postural tremor as first symptom of Huntington disease].
    Bernard E; Broussolle E; Thobois S
    Rev Neurol (Paris); 2010 Oct; 166(10):841-3. PubMed ID: 20226492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone in treatment of choreoathetosis of Huntington's disease.
    Parsa MA; Szigethy E; Voci JM; Meltzer HY
    J Clin Psychopharmacol; 1997 Apr; 17(2):134-5. PubMed ID: 10950488
    [No Abstract]   [Full Text] [Related]  

  • 19. Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD).
    Harris KL; Kuan WL; Mason SL; Barker RA
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):622-630. PubMed ID: 32229581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.